Repare Therapeutics Inc. (RPTX) Provides Business and Clinical Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Six dead in 'stampede-like' incident at India temple, ANI says
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
March 3, 2025 7:05 AM ESTInitial clinical readout from Phase 1 RP-3467 (Pol ATPase/helicase inhibitor) POLAR trial expected in Q3 2025
Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025
Company reducing its workforce by approximately 75%
$152.8 million in cash and cash equivalents and marketable securities provides runway to late-2027
Exploring partnerships across portfolio, including for Lunre+Camo
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported... More
